Hot Dividend Stocks To Buy For 2015

Hot Dividend Stocks To Buy For 2015: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors' Opinion:

• [By Ben Levisohn]

  The fundamentals of the biotech industry appear strong as measured by a robust list of ongoing and expected product launches. Large-cap biotech companies under our coverage (Alexion Pharmaceuticals, Amgen, Celgene, Gilead, Vertex Pharmaceuticals (VRTX)) all have ongoing or anticipated product launches in 2015. These launches…AbbVie (ABBV) / Enanta Pharmaceuticals (ENTA) Viekirax + Exviera for hepatitis C…Other high-visibility launches include the expected launches of PCSK9 antibodies, evolocumab from Amgen and alirocumab from Sanofi (SNY) / Regeneron (REGN) for high cholesterol, anticipated in 3Q:15. Although the expectation is for a slow ramp-up until cardiovascular outcome data (no later than 2017), the market is large enough to allow fast launches. For Celgene, Gilead, Medivation (MDVN) and Vertex, the launches are for their most important products; therefore the progress of the launches will be particularly important to watch.

• [By WWW.DAILYFINANCE.COM]

  www.gopro.com Now that it's nearly over, we can definitively say that 2014 has been one of the best years for initial public stock offerings in history. In terms of proceeds raised from IPOs, 2014 will challenge or even exceed the year 2000. Which is saying something: That was the height of the dot.! com frenzy, when seemingly every new company with a website felt compelled to list on the stock exchange. As can be expected of a busy IPO year, some of 2014's new stock market titles have been runaway hits soaring above their issue price, while others have belly-flopped. Since we're heading into the most optimistic time of the year, we'll shine a light on the three best performers. In order of stock price appreciation, they are: GoPro (GPRO) 2014's current IPO front-runner is this company, maker of the popular action photography camera -- the one that's usually responsible for those hairy point-of-view videos posted on Facebook (FB) and other online sharing sites. GoPro's stock hit the market at the end of June priced at $24, and as if this writing it now stands at $70.72 for a muscular 195 percent total return. Although that's impressive, it should be noted that the current price is quite a bit lower than the stock's high of nearly $94, which it touched in early October. But then the camera was effectively blamed for the horrific accident that befell Formula One racing star Michael Schumacher -- although the journalist making the allegation later recanted -- and the shares cratered. The stock recovered after the company reported strong third-quarter earnings, and all seemed well again... until GoPro decided to float a secondary issue of stock. It'll sell 10.3 million fresh shares on the market, adding to the nearly 126 million currently outstanding. When secondary share issues are announced, a company's stock often takes a hit, since investors aren't too crazy about their existing stakes being diluted. Regardless, on a fundamental basis GoPro is a popular, if

• [By Johanna Bennett]

  Regeneron (REGN) climbed 3.2% after its partner Sanofi (SNY) said an experimental asthma drug produced good results in clinical trials. Sanofi climbed 1.9%.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-dividend-stocks! -to-buy-f! or-2015.html